GlassScriptPhysician profile
Benjamin Thomas Kilian
NPI 1336305341
$2,279.35
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $124 · 2021: $20.08 · 2022: $771 · 2023: $493 · 2024: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $909.97 | 2022-2024 | Andexxa |
| Ceribell, INC. | $384.38 | 2023-2024 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Janssen Pharmaceuticals, INC | $261.01 | 2022 | |
| Inari Medical, INC. | $164.64 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $154.67 | 2022 | |
| Biosense Webster, INC. | $124.99 | 2019 | |
| Portola Pharmaceuticals, LLC | $124.00 | 2020 | |
| La Jolla Pharmaceutical Company | $116.10 | 2023 | Giapreza |
| Gilead Sciences, INC. | $20.08 | 2021 | |
| Purdue Pharma L.P. | $19.51 | 2023 | Nalmefene Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kilian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.